Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors	Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, liver disorder, neoplasm, stomach disorder, uterine disorder	Active, not recruiting	Phase 1 / Phase 2	2026-02-24		NCT05438420

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Merck Sharp & Dohme LLC	650
Qurient Co., Ltd.	4

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asan Medical Center	Seoul	South Korea	131
CHA Bundang Medical Center	Seongnam-si	South Korea	2
Norton Cancer Institute	Louisville	United States	26
Samsung Medical Center	Seoul	South Korea	170
Seoul National University Hospital	Seoul	South Korea	183
Severance Hospital	Seoul	South Korea	62
University of Southern California	Los Angeles	United States	110